Razelle Kurzrock, MD

Razelle Kurzrock, MD

Chief, Division of Hematology and Oncology
UCSD School of Medicine
Senior Deputy Director, Clinical Science
Director, Center for Personalized Cancer Therapy
Director, Clinical Trials Office
UCSD Moores Cancer Center
San Diego, California 

Related Videos

Can you provide a specific patient example -- in a patient with EGFR-positive NSCLC -- where ctDNA may redirect treatment? Video

Can you provide a specific patient example -- in a patient with EGFR-positive NSCLC -- where ctDNA may redirect treatment?

Can you provide a specific patient example — in a patient with EGFR-positive NSCLC — where ctDNA may redirect treatment?

How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information? Video

How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information?

How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information? Why are the results from these two tests sometimes divergent in the same patient?

Among the platforms available for NGS comprehensive genomic profiling, what features do you look for when selecting an NGS platform? What do you use in your precision cancer clinic? Video

Among the platforms available for NGS comprehensive genomic profiling, what features do you look for when selecting an NGS platform? What do you use in your precision cancer clinic?

Among the platforms available for NGS comprehensive genomic profiling, what features do you look for when selecting an NGS platform? What do you use in your precision cancer clinic?

What are the validations that larger molecular profiling panels -- using NGS to interrogate several hundred genes and provide comprehensive genomic profiles -- are superior to targeted or hot spot panels? Video

What are the validations that larger molecular profiling panels -- using NGS to interrogate several hundred genes and provide comprehensive genomic profiles -- are superior to targeted or hot spot panels?

What are the validations demonstrating that larger molecular profiling panels — those that use NGS to interrogate several hundred genes and provide comprehensive genomic profiles— are superior to targeted or hot spot panels?

In what tumor subtypes -- based on what molecular targets (BRAF, EGFR, MEK, ALK-1, etc) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates and improved overall survival? Video

In what tumor subtypes -- based on what molecular targets (BRAF, EGFR, MEK, ALK-1, etc) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates and improved overall survival?

In what tumor subtypes — and based on what specific molecular targets (BRAF, EGFR, MEK, ALK-1 and others, including MSI) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates, ...